XWELL PE Ratio 2010-2025 | XWEL
Current and historical p/e ratio for XWELL (XWEL) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. XWELL PE ratio as of June 11, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| XWELL PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-06-11 | 0.95 | 0.00 | |
| 2025-03-31 | 1.02 | $-4.02 | 0.00 |
| 2024-12-31 | 1.51 | $-3.62 | 0.00 |
| 2024-09-30 | 1.73 | $-3.64 | 0.00 |
| 2024-06-30 | 1.80 | $-5.03 | 0.00 |
| 2024-03-31 | 1.69 | $-5.95 | 0.00 |
| 2023-12-31 | 1.74 | $-6.75 | 0.00 |
| 2023-09-30 | 2.25 | $-8.18 | 0.00 |
| 2023-06-30 | 4.00 | $-7.40 | 0.00 |
| 2023-03-31 | 7.20 | $-7.60 | 0.00 |
| 2022-12-31 | 7.20 | $-7.00 | 0.00 |
| 2022-09-30 | 15.40 | $-3.40 | 0.00 |
| 2022-06-30 | 13.80 | $-0.80 | 0.00 |
| 2022-03-31 | 22.60 | $0.00 | 0.00 |
| 2021-12-31 | 40.40 | $0.60 | 67.33 |
| 2021-09-30 | 29.40 | 0 | 0.00 |
| 2021-06-30 | 30.80 | $-3.00 | 0.00 |
| 2021-03-31 | 36.80 | $-32.40 | 0.00 |
| 2020-12-31 | 23.80 | $-67.00 | 0.00 |
| 2020-09-30 | 39.40 | $-67.00 | 0.00 |
| 2020-06-30 | 83.80 | $-165.81 | 0.00 |
| 2020-03-31 | 11.40 | $-328.83 | 0.00 |
| 2019-12-31 | 40.20 | $-390.64 | 0.00 |
| 2019-09-30 | 86.40 | $-390.64 | 0.00 |
| 2019-06-30 | 116.40 | $-421.84 | 0.00 |
| 2019-03-31 | 144.00 | $-384.64 | 0.00 |
| 2018-12-31 | 192.00 | $-1,368.14 | 0.00 |
| 2018-09-30 | 180.00 | $-1,368.14 | 0.00 |
| 2018-06-30 | 348.00 | $-1,476.15 | 0.00 |
| 2018-03-31 | 864.00 | $-1,752.18 | 0.00 |
| 2017-12-31 | 1644.00 | $-1,080.11 | 0.00 |
| 2017-09-30 | 1668.00 | $-1,368.14 | 0.00 |
| 2017-06-30 | 1980.00 | $-1,536.15 | 0.00 |
| 2017-03-31 | 2604.00 | $-1,968.20 | 0.00 |
| 2016-12-31 | 2556.00 | $-1,896.19 | 0.00 |
| 2016-09-30 | 3228.00 | $-1,608.16 | 0.00 |
| 2016-06-30 | 2268.00 | $-2,640.26 | 0.00 |
| 2016-03-31 | 1968.00 | $-2,856.29 | 0.00 |
| 2015-12-31 | 2964.00 | $-3,360.34 | 0.00 |
| 2015-09-30 | 6720.00 | $-13,201.32 | 0.00 |
| 2015-06-30 | 6720.00 | $-13,681.37 | 0.00 |
| 2015-03-31 | 7800.00 | $-13,921.39 | 0.00 |
| 2014-12-31 | 6600.00 | $-14,641.46 | 0.00 |
| 2014-09-30 | 11400.00 | $-4,800.48 | 0.00 |
| 2014-06-30 | 41040.00 | $-4,440.44 | 0.00 |
| 2014-03-31 | 41640.00 | $-4,680.47 | 0.00 |
| 2013-12-31 | 35520.00 | $-4,920.49 | 0.00 |
| 2013-09-30 | 34440.00 | $-7,440.74 | 0.00 |
| 2013-06-30 | 38040.00 | $-8,040.80 | 0.00 |
| 2013-03-31 | 38040.00 | $-10,801.08 | 0.00 |
| 2012-12-31 | 34440.00 | $-14,521.45 | 0.00 |
| 2012-09-30 | 34800.00 | $-12,001.20 | 0.00 |
| 2012-06-30 | 46320.00 | $-13,681.37 | 0.00 |
| 2012-03-31 | 19800.00 | $-12,481.25 | 0.00 |
| 2011-12-31 | 11880.00 | $-9,240.92 | 0.00 |
| 2011-09-30 | 17040.00 | $-9,240.92 | 0.00 |
| 2011-06-30 | 14640.00 | $-11,401.14 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.005B | $0.034B |
| XWELL Inc. is a health and wellness holding company. Its operating brands include XpresCheck(R), XpresSpa(R), Treat(TM) and HyperPointe. XpresSpa is a retailer of wellness services and related products. Treat is a travel health and wellness brand. XpresCheck is a provider of Covid-19 screening and diagnostic testing in partnership with the CDC and Concentric by Ginkgo. HyperPointe is a digital healthcare and data analytics relationship company. XWELL Inc., formerly known as XpresSpa Group Inc., is based in NEW YORK. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $145.009B | 27.20 |
| Elevance Health (ELV) | United States | $86.741B | 11.19 |
| CVS Health (CVS) | United States | $81.290B | 10.10 |
| Cencora (COR) | United States | $55.092B | 19.17 |
| DiDi Global (DIDIY) | China | $23.485B | 35.64 |
| Natera (NTRA) | United States | $22.560B | 0.00 |
| BioMerieux (BMXMF) | France | $16.856B | 0.00 |
| Solventum (SOLV) | United States | $13.071B | 13.84 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.026B | 0.00 |
| ICON (ICLR) | Ireland | $11.688B | 10.87 |
| Revvity (RVTY) | United States | $11.345B | 19.52 |
| CochLear (CHEOY) | Australia | $11.134B | 0.00 |
| Doximity (DOCS) | United States | $10.995B | 50.90 |
| Viatris (VTRS) | United States | $10.610B | 3.65 |
| Avantor (AVTR) | United States | $9.329B | 13.55 |
| HealthEquity (HQY) | United States | $9.272B | 40.61 |
| Medpace Holdings (MEDP) | United States | $8.792B | 23.35 |
| Sonic Healthcare (SKHHY) | Australia | $8.450B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.416B | 14.53 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.450B | 26.21 |
| BrightSpring Health Services (BTSG) | United States | $3.875B | 35.87 |
| Sotera Health (SHC) | United States | $3.491B | 19.84 |
| Surgery Partners (SGRY) | United States | $2.989B | 38.87 |
| Alignment Healthcare (ALHC) | United States | $2.898B | 0.00 |
| Concentras Parent (CON) | United States | $2.816B | 16.27 |
| Organon (OGN) | United States | $2.610B | 2.77 |
| GeneDx Holdings (WGS) | United States | $1.983B | 76.39 |
| Progyny (PGNY) | United States | $1.923B | 42.32 |
| Ardent Health Partners (ARDT) | United States | $1.920B | 8.18 |
| Premier (PINC) | United States | $1.884B | 14.30 |
| PACS (PACS) | United States | $1.629B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.622B | 32.43 |
| Teladoc Health (TDOC) | United States | $1.298B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.213B | 9.23 |
| Establishment Labs Holdings (ESTA) | $1.124B | 0.00 | |
| CareDx (CDNA) | United States | $1.105B | 17.26 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.011B | 0.00 |
| Agilon Health (AGL) | United States | $0.944B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.843B | 7.89 |
| QDM (QDMI) | Hong Kong, SAR China | $0.752B | 0.00 |
| Nutex Health (NUTX) | United States | $0.651B | 9.85 |
| Embecta (EMBC) | United States | $0.592B | 3.99 |
| LifeMD (LFMD) | United States | $0.553B | 0.00 |
| Enhabit (EHAB) | United States | $0.543B | 44.67 |
| InnovAge Holding (INNV) | United States | $0.514B | 0.00 |
| SBC Medicals (SBC) | United States | $0.495B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.474B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.470B | 10.58 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.445B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.258B | 0.00 |
| Oncology Institute (TOI) | United States | $0.237B | 0.00 |
| Beauty Health (SKIN) | United States | $0.202B | 0.00 |
| DocGo (DCGO) | United States | $0.156B | 25.50 |
| KindlyMD (KDLY) | United States | $0.150B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.104B | 0.00 |
| So-Young (SY) | China | $0.090B | 0.00 |
| OncoCyte (OCX) | United States | $0.079B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.075B | 0.00 |
| KindlyMD (NAKA) | United States | $0.070B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.060B | 0.00 |
| NeueHealth (NEUE) | United States | $0.060B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.057B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.056B | 0.00 |
| Biodesix (BDSX) | United States | $0.048B | 0.00 |
| ModivCare (MODV) | United States | $0.047B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.029B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.013B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.010B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |